Metabolic Syndrome Is Associated With Poor Prognosis in Patients With Breast Cancer Receiving Neoadjuvant Therapy
Youzhao Ma, Jingyang Zhang, Dechuang Jiao, Xiuchun Chen, Zhenzhen Liu · 2024
Read Metabolic Syndrome Is Associated With Poor Prognosis in Patients With Breast Cancer Receiving Neoadjuvant Therapy by Youzhao Ma, Jingyang Zhang, Dechuang Jiao, Xiuchun Chen, Zhenzhen Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11660380.txt.
Description
Youzhao Ma and co-authors link metabolic syndrome to worse breast cancer outcomes in a 2024 study. The syndrome bundles belly fat, blood pressure, sugar, and lipid problems. Among 910 patients treated with chemotherapy before surgery at one center, eighteen percent had the syndrome. Most tumors were stage two or three.
Patients with the syndrome reached complete tumor disappearance less often. Five-year disease-free survival ran about seventy-three percent for them, against eighty-four percent without the syndrome. Overall survival showed the same gap. The disadvantage held among premenopausal women as well. Links with menopause status and stage were also found. The authors argue metabolic health belongs in treatment planning, not just in long-term prevention talk.
Catalog record
| CREATOR | Youzhao Ma, Jingyang Zhang, Dechuang Jiao, Xiuchun Chen, Zhenzhen Liu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |